HOXB9 Mediates Resistance to Chemotherapy and Patient Outcomes Through the TGFβ Pathway in Pancreatic Cancer

Overview

Journal Oncotarget

Specialty Oncology

Date 2022 May 31

PMID 35634239

Authors

Naokazu Chiba

Shigeto Ochiai

Takahiro Gunji

Toshimichi Kobayashi

Toru Sano

Koichi Tomita

Shigeyuki Kawachi

Affiliations

Soon will be listed here.

Abstract

Background: Although HOXB9 induces tumor proliferation and chemoresistance in several cancer cells, little is known in pancreatic ductal adenocarcinoma (PDAC). In the present study, increased expression of HOXB9 in PDAC was associated with the induction of angiogenic factors and poor overall survival through the TGFβ pathway. Taken together, these results suggested that HOXB9 expression in PDAC could be a surrogate marker in clinical treatment.

Methods: , angiogenic factors, TGFβ signature, Epithelial Mesenchymal Transition (EMT) marker, and chemoresistance were examined in PDAC cell lines by HOXB9 knockdown system. And the reverse effect was confirmed by using TGFβ1 recombinant. Furthermore, in clinical specimens, the correlation between HOXB9 expression and TGFβ signature was analyzed, and the relationship with clinical outcomes were investigated.

Results: HOXB9 expression regulated the expression of TGFβ1 signature, angiogenic factors, and EMT markers , and TGFβ1 recombinant made the reverse effect of these results. And HOXB9 expression regulated the resistance to chemotherapy (Gemcitabine and nab-Paclitaxel) and stem cell population. Moreover, increased HOXB9 expression was significantly associated with poor disease-free survival the prognosis for overall survival. And, a significant positive correlation was observed between HOXB9 expression and several TGFβ signatures in clinical specimens.

Conclusions: In conclusion, HOXB9 expression could mediate angiogenesis, EMT, and cancer stemness through the TGFβ pathway, thereby resulting in chemoresistance and poor overall outcomes in patients with pancreatic cancer. Our results suggested that HOXB9 may clinically serve as a novel surrogate biomarker.

Citing Articles

A pan-cancer analysis of homeobox family: expression characteristics and latent significance in prognosis and immune microenvironment.

Wang Y, Gao J, Ren Z, Shen Z, Gu W, Miao Q Front Oncol. 2025; 15:1521652.

PMID: 39980564 PMC: 11840236. DOI: 10.3389/fonc.2025.1521652.

HOXA9 versus HOXB9; particular focus on their controversial role in tumor pathogenesis.

Hjazi A, Jasim S, Al-Dhalimy A, Bansal P, Kaur H, Qasim M J Appl Genet. 2024; 65(3):473-492.

PMID: 38753266 DOI: 10.1007/s13353-024-00868-x.

Patient-derived organoids of pancreatic ductal adenocarcinoma for subtype determination and clinical outcome prediction.

Matsumoto K, Fujimori N, Ichihara K, Takeno A, Murakami M, Ohno A J Gastroenterol. 2024; 59(7):629-640.

PMID: 38684511 PMC: 11217054. DOI: 10.1007/s00535-024-02103-0.

Identification of HOXB9 to predict prognosis of endometrial cancer based on comprehensive bioinformatics analysis.

Xu Y, Zhang M, Shi Q, Cheng X, Du R, Li C Eur J Med Res. 2023; 28(1):79.

PMID: 36803556 PMC: 9936693. DOI: 10.1186/s40001-022-00979-3.

HOXB9 Overexpression Confers Chemoresistance to Ovarian Cancer Cells by Inducing ERCC-1, MRP-2, and XIAP.

Suh D, Park W, Kim M, Kim K, No J, Kim Y Int J Mol Sci. 2023; 24(2).

PMID: 36674764 PMC: 9865712. DOI: 10.3390/ijms24021249.

References

Cantile M, Schiavo G, Terracciano L, Cillo C . Homeobox genes in normal and abnormal vasculogenesis. Nutr Metab Cardiovasc Dis. 2008; 18(10):651-8. DOI: 10.1016/j.numecd.2008.08.001. View

Grier D, Thompson A, Kwasniewska A, McGonigle G, Halliday H, Lappin T . The pathophysiology of HOX genes and their role in cancer. J Pathol. 2005; 205(2):154-71. DOI: 10.1002/path.1710. View

Chen H, Sukumar S . HOX genes: emerging stars in cancer. Cancer Biol Ther. 2003; 2(5):524-5. DOI: 10.4161/cbt.2.5.525. View

Warot X, Lakkaraju S, Favier B, Haack H, Birling C, Dierich A . Specific and redundant functions of the paralogous Hoxa-9 and Hoxd-9 genes in forelimb and axial skeleton patterning. Development. 1996; 122(2):461-72. DOI: 10.1242/dev.122.2.461. View

Wang L, Li P, Hu W, Xia Y, Hu C, Liu L . CD44CD24 subset of PANC-1 cells exhibits radiation resistance via decreased levels of reactive oxygen species. Oncol Lett. 2017; 14(2):1341-1346. PMC: 5529798. DOI: 10.3892/ol.2017.6301. View

Wei H, Yin T, Zhu Z, Shi P, Tian Y, Wang C . Expression of CD44, CD24 and ESA in pancreatic adenocarcinoma cell lines varies with local microenvironment. Hepatobiliary Pancreat Dis Int. 2011; 10(4):428-34. DOI: 10.1016/s1499-3872(11)60073-8. View

Siegel R, DeSantis C, Virgo K, Stein K, Mariotto A, Smith T . Cancer treatment and survivorship statistics, 2012. CA Cancer J Clin. 2012; 62(4):220-41. DOI: 10.3322/caac.21149. View

Ma S, Qu W, Mao L, Zhu Z, Jia L, Zhao L . Antitumor effects of oncolytic adenovirus armed with Drosophila melanogaster deoxyribonucleoside kinase in colorectal cancer. Oncol Rep. 2012; 27(5):1443-50. DOI: 10.3892/or.2012.1665. View

Chiba N, Ozawa Y, Hikita K, Okihara M, Sano T, Tomita K . Increased expression of HOXB9 in hepatocellular carcinoma predicts poor overall survival but a beneficial response to sorafenib. Oncol Rep. 2017; 37(4):2270-2276. DOI: 10.3892/or.2017.5474. View

10.

Hoshino Y, Hayashida T, Hirata A, Takahashi H, Chiba N, Ohmura M . Bevacizumab terminates homeobox B9-induced tumor proliferation by silencing microenvironmental communication. Mol Cancer. 2014; 13:102. PMC: 4023179. DOI: 10.1186/1476-4598-13-102. View

11.

Li D, Xie K, Wolff R, Abbruzzese J . Pancreatic cancer. Lancet. 2004; 363(9414):1049-57. DOI: 10.1016/S0140-6736(04)15841-8. View

12.

Katsuno Y, Lamouille S, Derynck R . TGF-β signaling and epithelial-mesenchymal transition in cancer progression. Curr Opin Oncol. 2012; 25(1):76-84. DOI: 10.1097/CCO.0b013e32835b6371. View

13.

Pickup M, Novitskiy S, Moses H . The roles of TGFβ in the tumour microenvironment. Nat Rev Cancer. 2013; 13(11):788-99. PMC: 4025940. DOI: 10.1038/nrc3603. View

14.

Seki H, Hayashida T, Jinno H, Hirose S, Sakata M, Takahashi M . HOXB9 expression promoting tumor cell proliferation and angiogenesis is associated with clinical outcomes in breast cancer patients. Ann Surg Oncol. 2012; 19(6):1831-40. DOI: 10.1245/s10434-012-2295-5. View

15.

Chiba N, Comaills V, Shiotani B, Takahashi F, Shimada T, Tajima K . Homeobox B9 induces epithelial-to-mesenchymal transition-associated radioresistance by accelerating DNA damage responses. Proc Natl Acad Sci U S A. 2011; 109(8):2760-5. PMC: 3286905. DOI: 10.1073/pnas.1018867108. View

16.

Chiba N, Sunamura M, Nakagawa M, Koganezawa I, Yokozuka K, Kobayashi T . Overexpression of hydroxyproline via EGLN/HIF1A is associated with distant metastasis in pancreatic cancer. Am J Cancer Res. 2020; 10(8):2570-2581. PMC: 7471362. View

17.

Chen F, Capecchi M . Paralogous mouse Hox genes, Hoxa9, Hoxb9, and Hoxd9, function together to control development of the mammary gland in response to pregnancy. Proc Natl Acad Sci U S A. 1999; 96(2):541-6. PMC: 15172. DOI: 10.1073/pnas.96.2.541. View

18.

Hayashida T, Takahashi F, Chiba N, Brachtel E, Takahashi M, Godin-Heymann N . HOXB9, a gene overexpressed in breast cancer, promotes tumorigenicity and lung metastasis. Proc Natl Acad Sci U S A. 2010; 107(3):1100-5. PMC: 2824265. DOI: 10.1073/pnas.0912710107. View